Segmed and Verily Unite to Supercharge Medical AI with Imaging Data

PALO ALTO, Calif. – February 25, 2026 – In a significant move to accelerate data-driven medical innovation, real-world data provider Segmed announced a partnership today with Verily, a precision health AI company. The collaboration will integrate Segmed’s vast library of de-identified medical imaging data into Verily’s secure, self-serve AI platform, creating a powerful new resource for researchers in academia, life sciences, and healthcare.

This partnership aims to break down long-standing barriers to medical research by providing streamlined access to high-quality, diverse datasets essential for developing next-generation diagnostics and therapies. By combining Segmed's extensive data repository with Verily's advanced analytical environment, the initiative promises to unlock new insights in precision health, starting with a critical focus on breast cancer.

A New Engine for Precision Health

The collaboration represents a powerful synergy between two key players in the health technology ecosystem. Segmed brings to the table a global data platform containing approximately 150 million de-identified imaging exams. This massive repository spans a wide range of modalities, including CT, MRI, X-ray, ultrasound, and mammography, providing the raw material needed to train and validate sophisticated AI models.

This data will now be accessible within Verily's Pre Exchange and Workbench platform, an AI-native ecosystem designed to harmonize and analyze complex, multimodal health data. Verily's platform is purpose-built to handle the entire AI model development lifecycle—from data exploration and cohort building to model training, validation, and deployment—all within a secure and scalable cloud environment. Researchers can leverage a suite of integrated tools, from standard data science applications to specialized biomedical software, to accelerate their work.

"Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," said David Gascoigne, Chief Executive Officer of Segmed. "By partnering with Verily, we're expanding responsible access to high-quality, de-identified imaging datasets, helping researchers generate insights faster to accelerate the development of diagnostics and therapies."

The initial dataset made available through the partnership underscores its potential impact. It features a longitudinal cohort of breast cancer patients who underwent digital breast tomosynthesis (DBT) exams and have biopsy-proven malignant lesions. This type of high-quality, curated data is invaluable for developing more accurate AI-driven screening tools and understanding disease progression.

"This partnership with Segmed is an important step forward in advancing AI powered precision health," said Bharat Rajagopal, Chief Revenue Officer at Verily. "By integrating Segmed's curated real-world imaging and associated clinical data into Pre, we are empowering researchers with the comprehensive, multimodal data resources they need to unlock new insights and accelerate discovery."

Navigating the Ethical Frontier of Data

As the use of artificial intelligence in healthcare expands, the partnership places a strong emphasis on navigating the critical challenges of patient privacy and data security. The collaboration is founded on a "privacy-first" approach, ensuring that the vast potential of real-world data is harnessed responsibly.

Segmed's core offering is built on providing access to thoroughly de-identified data, a process that involves stripping patient identifiers in accordance with strict regulatory standards like HIPAA to protect patient confidentiality. The integrity of this de-identification is fundamental to the ethical use of health data for research.

This anonymized data is then made available within Verily's highly secure Workbench, which functions as a trusted research environment. Verily's platform is buttressed by robust security protocols, holding industry-recognized certifications such as SOC 2 Type II and ISO/IEC 27001, and undergoes independent audits for HIPAA compliance. Data is protected by strong encryption both at rest and in transit, with access tightly controlled and monitored through granular, role-based permissions.

Critically, the platform includes governance features that prevent the unauthorized download or exfiltration of data. Researchers can analyze the data within the secure perimeter of the Workbench, but they cannot remove it. This model allows for widespread access for discovery while maintaining strict control over the data itself, striking a crucial balance between enabling innovation and upholding patient privacy.

Democratizing Access to Medical Discovery

Historically, access to large-scale, research-grade medical imaging datasets has been a significant bottleneck for innovation. Such data is often siloed within individual hospital systems, difficult to aggregate, and expensive to procure and process. This partnership directly addresses that challenge by significantly lowering the barrier to entry for researchers across the globe.

By making Segmed's data available through Verily's self-serve platform, the collaboration democratizes access beyond just large, well-funded pharmaceutical companies and tech giants. Verily has already made strides in this area by offering a free "Standard tier" account, enabling individual academic researchers to explore and analyze powerful biomedical datasets. This move fosters a more inclusive research ecosystem where innovative ideas can come from a wider range of institutions and investigators.

This strategy also positions the combined offering strongly within the competitive landscape of health data platforms. While companies like Tempus and Flatiron Health have made significant inroads with clinical and oncology data, the Segmed-Verily partnership creates a uniquely powerful resource by marrying a massive, multimodal imaging dataset with a sophisticated, AI-ready analytical platform. This integrated approach is designed to accelerate scientific workflows, reduce research costs, and ultimately speed up the translation of discoveries from the lab to the clinic.

The Real-World Impact on AI Development

The ultimate goal of this collaboration is to fuel breakthroughs in healthcare AI by providing the high-quality data that algorithms need to learn and improve. AI models are only as good as the data they are trained on, and real-world data presents unique challenges, including heterogeneity from different scanners and protocols, inherent biases, and the need for expert annotation.

This partnership tackles these issues head-on. Segmed provides a diverse, global dataset, which is essential for building AI models that are robust and generalizable across different patient populations and clinical settings. Verily’s platform, in turn, is engineered to ingest and harmonize these disparate data sources into a standardized, AI-ready format. This crucial step cleans and prepares the data, saving researchers countless hours of manual work and allowing them to focus on generating insights.

With this powerful new resource, researchers can pursue answers to some of medicine's most pressing questions. They can develop AI tools that detect cancer earlier and more accurately from a routine scan, create algorithms that predict a patient's response to a specific therapy based on subtle imaging biomarkers, or model disease progression to enable more proactive and personalized care. By connecting vast data resources with powerful analytical tools in a secure environment, Segmed and Verily are building a vital piece of infrastructure for the future of medicine.